{"nct_id":"NCT06472076","title":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2024-06-10","start_date_type":"ACTUAL","primary_completion_date":"2027-02-02","primary_completion_date_type":"ESTIMATED","completion_date":"2027-02-02","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GSK"]}